Evidence map›Paper›PMID 39340003›Full record

ArticleVaccines2024

Short-Term Active Safety Surveillance of the Spikevax and Nuvaxovid Priming Doses in Australia.

Renee Reynolds, Evelyn Tay, Michael Dymock, Lucy Deng, Catherine Glover, Laura K Lopez, Yuanfei Anny Huang, Patrick Cashman, Alan Leeb, Julie A Marsh and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Renee ReynoldsPopulation Health, Hunter New England Local Health District, Wallsend, NSW 2287, Australia.ORCID 0000-0002-9849-551X
Evelyn TayWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Perth, WA 6009, Australia.
Michael DymockWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Perth, WA 6009, Australia.ORCID 0000-0003-4881-2860
Lucy DengNational Centre for Immunisation Research and Surveillance, Westmead, Sydney, NSW 2145, Australia.ORCID 0000-0003-0066-2218
Catherine GloverNational Centre for Immunisation Research and Surveillance, Westmead, Sydney, NSW 2145, Australia.
Laura K LopezNational Centre for Immunisation Research and Surveillance, Westmead, Sydney, NSW 2145, Australia.
Yuanfei Anny HuangNational Centre for Immunisation Research and Surveillance, Westmead, Sydney, NSW 2145, Australia.
Patrick CashmanNational Centre for Immunisation Research and Surveillance, Westmead, Sydney, NSW 2145, Australia.ORCID 0000-0001-7183-1360
Alan LeebCentre for Child Health Research, University of Western Australia, Nedlands, Perth, WA 6009, Australia.
Julie A MarshWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Perth, WA 6009, Australia.
Tom SnellingWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Perth, WA 6009, Australia.ORCID 0000-0003-4670-0638
Nicholas WoodNational Centre for Immunisation Research and Surveillance, Westmead, Sydney, NSW 2145, Australia.
Kristine MacartneyNational Centre for Immunisation Research and Surveillance, Westmead, Sydney, NSW 2145, Australia.

Funding

Australian Government Department of Health and Aged Care Health/20-21/PH20/17578
6 · The paper itself

Abstract

Australia commenced administration of the Spikevax (Moderna mRNA-1273) COVID-19 vaccine in August 2021 and Nuvaxovid (Novavax NVX-CoV2373) in January 2022. This study describes the short-term safety profile of priming doses of the Spikevax and Nuvaxovid vaccines given between September 2021 and September 2023. Online surveys were sent via AusVaxSafety, Australia's active vaccine safety surveillance system, three and eight days after vaccination. A total of 131,775 day 3 surveys were sent, with a response rate of 38.5% (

Indexed as

active surveillanceadverse eventsCOVID-19ModernaNovavaxsafetyvaccine

Identifiers

PMID39340003
PMCPMC11435866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.